Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 10, 2025
Reporting Period: Single event date (April 10, 2025)
Business Context: The Company is an emerging growth corporation incorporated in Delaware, focused on precision cancer therapy. This filing reports a specific corporate event regarding intellectual property.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a non-financial corporate event.
Material Changes
Intellectual Property Filing: On April 10, 2025, the Company filed a key provisional patent application with the United States Patent and Trademark Office (USPTO).
Subject Matter: The application is entitled "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy."
Guidance, Outlook, and Risks
Management Commentary: The filing includes a press release (Exhibit 99.1) announcing the patent filing. No specific financial guidance or operational outlook was provided in the text of this report.
Risks and Forward-Looking Statements: The filing contains standard forward-looking statements regarding future results, strategy, and plans. Management cautions that actual results may differ materially due to known and unknown risks, uncertainties, and assumptions. The Company undertakes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the status and scope of the provisional patent application "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy" via the USPTO database.
- Review the full text of the press release attached as Exhibit 99.1 for additional technical details not summarized in the 8-K.
- Confirm the Company's current cash position and runway in the most recent 10-Q or 10-K, as this filing does not provide liquidity data.
- Monitor future filings for the conversion of this provisional application into a non-provisional patent.